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Abstract 
Background: The PSP (predilatation, sizing, post-dilatation)-technique was developed to 
improve the prognosis of patients after bioresorbable vascular scaffold (BVS) implantation. In 
acute coronary syndrome (ACS) the use of BVS is particularly demanding and carries some 
potential risk regarding aggressive lesion preparation, proper vessel sizing due to spasm and 
thrombus inside the artery. The aim herein, was to determine the long-term results of BVS 
stenting in ACS patients depending on the scaffold implantation technique. 
Methods: The present study  is a prospective, two-center study, which consisted of 182 
patients who underwent percutaneous coronary intervention (PCI) with BVS (Absorb, Abbott 
Vascular, Santa Clara, California, USA) implantation for the ACS. All patients were divided 
into two groups. The first consisted of 52 patients treated with the PSP-technique (PSP 
group). The second group enrolled 130 patients treated with a non-PSP procedure (non-PSP 
group).  
Results: The procedure was successful in all patients. The mean observation time was 28.8 ± 
16.5 months (median 28.3 months, interquartile range 24.0 [17.0–41.0] months). It was found 
that target vessel failure (TVF) was consistently reduced in patients using the PSP-technique 
as compared with the non-PSP group (5.8% vs. 17.7%, p = 0.03). Moreover, PSP-technique 
was superior to non-PSP-technique concerning major adverse cardiac events (MACE) (3.7% 
vs. 22.3%, p = 0.02). Logistic regression analysis revealed that the use of PSP technique 
significantly decreased the risk of target vessel revascularization (odds ratio [OR] 0.11, p = 
0.01), TVF (OR 0.28, p = 0.03) and MACE (OR 0.29, p = 0.02). 
Conclusions: The PSP-technique for BVS implantation improves long-term results and 
should also be recommended for newer generations of the bioresorbable scaffold. 
Key words: acute coronary syndrome, acute myocardial infarction, STEMI, NSTEMI, 
angiography, coronary, bioresorbable devices/polymers 
 
 
Introduction 
Bioresorbable vascular scaffolds (BVSs) are a first-generation technology introduced 
to overcome the limitations of metallic stents [1, 2]. Unfortunately, recent reports of 
randomized trials revealed several negative results compared with drug eluting stents (DESs) 
[3–5], especially a higher rate of target-vessel myocardial infarction and scaffold thrombosis 
[6]. Thick struts of BVS delay endothelialization, correlate with flow disturbance and, in 
consequence, increase the risk of scaffold thrombosis [7]. Different constructions and 
mechanical properties make the proper choice of scaffold diameter and its implantation 
crucial to the results of the procedure. The recent studies have focused on optimal pre-
dilatation, sizing of the vessel and post-dilatation to improve treatment results. Ortega-Paz et 
al. [8] presented the predictive value of PSP (predilatation, sizing, post-dilatation) scores on 
clinical outcomes. It was an independent predictor of a one-year device-oriented composite 
endpoint composed of cardiac death, target vessel myocardial infarction, and clinically driven 
target lesion revascularization. However, the use of BVS and its implantation using PSP-
technique in acute coronary syndrome (ACS), the most prothrombotic form of atherosclerosis, 
is demanding and carries some potential risk regarding aggressive lesion preparation, proper 
vessel sizing due to spasm and thrombus inside the artery. Moreover, BVS has raised 
concerns regarding over-expansion, disruption, and the effect of post-dilatation following 
implantation [9, 10]. 
Evidence regarding optimal BVS implantation technique in ACS remains limited. 
These data would be useful in subsequent generations of bioresorbable scaffolds. The aim of 
the study is to determine results of BVS stenting in ACS depending on scaffold implantation 
technique. 
 
Methods 
Study design 
In this prospective, two-center study, a total of 182 patients were consecutively 
selected who underwent percutaneous coronary intervention (PCI) with BVS (Absorb, Abbott 
Vascular, Santa Clara, California, USA) implantation for ACS between December 2012 and 
October 2015. Eligible patients were hemodynamically stable with left ventricular ejection 
fraction > 30% and had a life expectancy of at least 5 years. In angiography, they had at least 
one significant coronary artery stenosis, with no restrictions as to the number, severity or 
lesion location. Patients were divided into two groups, depending on implantation technique. 
The first consisted of 52 patients treated with the PSP-technique (PSP group). The second 
group enrolled 130 patients treated with a non-PSP procedure (non-PSP group). In this group, 
predilatation was performed in 120 (92.3%) and 17 (13.1%) in post-dilatation patients, 
respectively. 
Patients excluded from the study were with: cardiogenic shock, the life expectancy of 
less than 1 year. The use of metallic stents during the index procedure and the target vessel 
reference diameter were < 2.3 mm and > 3.7 mm by visual estimate. Detailed exclusion 
criteria are presented in Table 3. 
Ethics approval was obtained from the Institutional Review Committees in each 
institution. The study was performed following ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments.  
 
Implantation technique 
The PCI procedure was performed according to current PCI guidelines. PSP technique 
is the recommended optimal implantation method of ABSORB BVS. The definition was 
derived from the GHOST registry and included three steps: predilatation, proper vessel sizing, 
and post-dilatation. In PSP group, these implantation criteria were met in all patients. 
Predilatation was performed using non-compliant (NC) balloon 1:1 ratio with reference vessel 
diameter (RVD) to obtain optimal lesion preparation. The alternative balloons (scoring or 
cutting) were considered if NC balloon was not completely expanded. Proper scaffold sizing 
was based on angiography guidance and online quantitative coronary angiography (QCA) 
according to RVD. During implantation, the balloon was inflated slowly with 2 atmospheres 
every 5 s, maintaining the final pressure for 20 s in the scaffold. Post-dilatation was carried 
out with an NC balloon > 1:1 ratio with RVD up to 0.5 mm at ≥ 16 atmospheres to confirm 
the full expansion of the scaffold and optimize overlap zone. In non-PSP group pre- and post-
dilatation were at the discretion of the operator, however, were performed according to the 
principles of PSP technique. 
 
Peri- and post-procedural pharmacotherapy 
Each patient naive to antiplatelet therapy, received a loading dose of 300 mg 
acetylsalicylic acid followed by the maintenance daily dose of 75 mg and one of the 
following: clopidogrel 600 mg (n = 97; 53.3%), prasugrel 60 mg (n = 1; 0.5%), or ticagrelor 
180 mg (n = 84; 46.2%) in loading doses before or immediately after PCI, followed by a 
maintenance dose of clopidogrel (75 mg o.d.), prasugrel (10 mg o.d.), or ticagrelor (90 mg 
twice daily) for a minimum of 12 months. The decision about the continuation of dual 
antiplatelet therapy (DAPT) after 12 months was made individually for the patient depending 
on risk  of thrombosis. A bolus of unfractionated heparin, 100 U/kg was administered 
intravenously during the procedure. The remaining pharmacotherapy was applied according to 
contemporary guidelines. 
 
Data collection 
All data were collected in an electronic database. Clinical follow-up was obtained 30 
days, 6 months, 1 year and every following year after the procedure by direct contact with 
patients or telephone interview, and additionally a review of medical reports if the patient had 
been hospitalized. 
Patients were monitored the for the following endpoints: death, myocardial infarction 
(MI), scaffold thrombosis, target lesion revascularization (TLR), target vessel 
revascularization (TVR) and target vessel failure (TVF), defined as cardiac death, target 
vessel MI, and TVR. Additionally, cumulative major adverse cardiac events (MACE) rate, 
composed of cardiac death, non-fatal infarction or reintervention were analyzed. 
 
Definitions 
ST-segment elevation myocardial infarction (STEMI) was defined as an 
electrocardiographic ST-segment elevation concomitant with characteristic symptoms of 
myocardial ischemia and subsequent release of biomarkers of myocardial necrosis [11]. New 
or presumed new left bundle branch block has been considered a STEMI equivalent. Non-ST-
segment elevation myocardial infarction (NSTEMI) definition involved the presence of 
angina chest pain with a marked elevation of myocardial necrosis biomarkers and no evidence 
of ST-segment elevation in the electrocardiogram (ECG). Unstable angina was diagnosed in 
patients with symptoms of myocardial ischemia and no troponin elevation, with or without 
ECG changes indicative of ischemia (e.g., ST-segment depression or transient elevation or 
new T wave inversion) [12]. Death was defined as all-cause mortality during the follow-up. 
Scaffold thrombosis was determined according to the Academic Research Consortium 
definition [13, 14]. TLR was set as a target segment reintervention including 5 mm proximal 
and distal to the scaffold.  
Revascularization was indicated if symptoms of myocardial ischemia occurred, and 
positive stress test, electrocardiographic evidence of ischemia at rest, and/or > 70% diameter 
in-lesion stenosis on angiography were observed. A procedure was angiographically 
successful with residual diameter stenosis of less than 30% after scaffold implantation in 
combination with Thrombolysis in Myocardial Infarction (TIMI) III coronary flow. Procedure 
success was defined as angiographic success in the absence of in-hospital MACE. 
 
Results 
The baseline characteristics of the study groups are presented in Table 1. According to 
these data, clinical presentation and prevalence of cardiovascular risk factors did not differ 
between groups (for all, p > 0.05). In both, middle aged men with hypertension predominated. 
About one-third of patients suffered from diabetes mellitus. It was noticed that previous MI 
was significantly more often in the non-PSP group. In turn, the PSP group had  more complex 
lesions, such as higher rate of left main disease, target bifurcation lesion, and significant 
calcification  . There was a significantly higher rate of lesions of type B2/C in the non-PSP 
group (Table 2). 
Total length of the implanted scaffold was significantly higher in the PSP group 
compared with the non-PSP group (26.8 ± 12.5 mm vs. 22.5 ± 10.3 mm, p = 0.02). 
Quantitative coronary analysis demonstrated a significant more upper reference vessel 
diameter and lower post-procedural diameter stenosis in patients treated with PSP technique. 
Procedural success was obtained in all patients. In three cases coronary dissection 
occurred and was successfully covered with an additional scaffold. No peri-procedural major 
adverse cardiac events were reported. Detailed angiographic characteristics are presented in 
Table 2. 
Complete follow-up was available in 88.5% after 12 months, 83,5% after 24 months, 
and 63.2% after 36 months. The mean   observation time was 28.8 ± 16.5 months (median 
28.3 months, interquartile range 24.0 [17.0–41.0] months). The rate of all-cause death and 
cardiac death was similar in both groups. There was a trend to a higher incidence of MI and 
TLR in the non-PSP-technique group, however, it was not statistically significant. Scaffold 
thrombosis occurred only in 1 patient during hospitalization (definite sub-acute thrombosis). 
No further scaffold thrombosis occurred at follow-up. TVF was consistently reduced in 
patients using the PSP technique as compared with non-PSP-technique group (5.8% vs. 
17.7%, p = 0.03). Moreover, PSP-technique was superior to non-PSP-technique concerning 
MACE (3.7% vs. 22.3%, p = 0.02). 
The logistic regression analysis revealed that use of the PSP technique significantly 
decreased the risk of TVR (odds ratio [OR] = 0.11, p = 0.01), TVF (OR = 0.28, p = 0.03) and 
MACE (OR = 0.29, p = 0.02). 
 
Discussion 
 In this study, it was found that pre-dilatation, proper sizing, and post-dilatation, cold 
PSP-technique, improve long-term clinical results of bioresorbable absorb scaffolds in 
patients with ACS. PSP-technique reduces the risk of TVR, TVF, and MACE by almost 8-
fold. 
Recently, preliminary results for BVS are not very encouraging. The main concerns 
regard thrombosis and restoration of vessel functionality at long-term follow-up. Data from 
the randomized ABSORB Japan (2 years), ABSORB III (2 years), ABSORB II (3 years), and 
AIDA (2-year mean follow-up) trials demonstrated a higher rate of very late scaffold 
thrombosis with BVS compared to CoCr-EES [3, 4, 15]. Increased strut thickness delays 
endothelialization and correlates with flow disturbance, increased risk of strut fracture and 
disruption because of overexpansion [16]. Additionally, BVSs are not as stretchable as 
metallic stents and cannot be expanded beyond specified limits. Due to these specific 
properties, implantation of BVS should be performed particularly carefully. PSP technique 
(precise pre-dilatation and vessel sizing before BVS implantation and post-dilation following 
implantation) was associated with lower risk of thrombotic events in context with a non-PSP 
technique [33]. Predilatation and proper vessel sizing increases the rate of successful device 
delivery and correct expansion. The data showed that a correct size of the vessel is the most 
critical determinant of event-free rate during the year subsequent to implantation [20, 21]. The 
MICAT authors suggested that very-late events could also be associated with a suboptimal 
sizing of the vessel [19]. In turn, an optimal post-dilation prevents adverse events by 
maximizing scaffold dimensions, embed struts into plaque, avoid acute malapposition, and 
reduce shear stress [21]. 
The PSP technique has been investigated for ABSORB BVS technology [17]. Firstly, 
it was considered as the five golden “P”s: prepare the lesion, properly size, pay attention to 
expansion limits, post-dilate with non-compliant balloon as well as pay attention to DAPT 
[18]. This concept was supported by a group of European experts in a consensus document 
regarding optimal implantation technique [16] and by results from  the MICAT registry (The 
Coronary Slow-flow and Microvascular Diseases Registry) [19]. In this study, optimal 
implantation technique significantly reduced the rate of scaffold thrombosis. The post-hoc 
analysis of the GHOST-EU registry showed a reduction of device-oriented composite 
endpoint at 1-year follow-up when all three steps of the PSP technique were performed 
correctly [20]. 
Moreover, a pooled analysis of the ABSORB trials (ABSORB II, III, CHINA, 
JAPAN, and EXTEND) revealed that an optimal PSP-technique was strongly associated with 
clinical outcomes during long-term follow-up [21]. The rationale for the use of BVS in the 
setting of the ACS are data suggesting that implantation of a temporary scaffold is associated 
with stabilization of atherosclerotic plaque without a permanent metallic cage. According to 
recent data, the safety and clinical outcomes of BVS in ACS patients are comparable to that of 
modern DESs [22]. From a retrospective study, it is also known that scaffold thrombosis can 
be reduced, when appropriate BVS size, pre- and post-dilatation were employed [23]. In the 
present study, the rate of scaffold thrombosis was not negligible and occurred in only 1 
patient in the non-PSP group who did not have post-dilatation. 
Although aggressive lesion preparation improves the rate of successful device 
delivery, predilatation potentially increases the risk of plaque disruption, thrombus 
mobilization, and distal embolism [24]. Usually, it is recommended to use semi- or non-
compliant balloons with a diameter 0.5 mm smaller or equal to the size of the planned device 
and characteristics [23]. In the present study, all lesions were pre-dilated in PSP group and 
92.3% lesions in non-PSP groups without complications. In all these cases, manual thrombus 
aspiration was applied before pre-dilatation. The overall procedural success rate was 100%, 
including all cases with evident thrombus. 
Due to the limited expansion and BVS sizes available, vessel sizing is crucial in 
performing accurate scaffold implantation, especially in patients with ACS. In this group, 
proper vessel sizing can be limited due to spasm and thrombus inside the artery [25, 26]. 
Scaffold diameter should be selected according to the reference vessel diameter. The gold 
standard of correct RVD estimation after proper pre-dilation, and excluded under expansion 
or malapposition is intravascular imaging [17]. Tanaka et al. [27] reported that patients treated 
with intravascular imaging guidance, post-dilation balloon/scaffold ratio was higher and final 
residual percentage stenosis was lower compared with those treated with an angio-guided 
approach. However, despite the angio- and QCA guided PSP technique has several 
limitations, such as limited information of the atherosclerotic plaque composition, limited 
visibility of the scaffold in the angiography, difficulties in the estimation of RVD, and 
uncertainty of possible scaffold under expansion or malapposition, these techniques are used 
in the three steps of implantation in most patients. This results from the still limited 
availability of optical coherence tomography and intravascular ultrasound due to high cost. In 
the current study the QCA guided approach dominated in the PSP group (65.4%), and 
angiography-guided approach in non-PSP group (93.2%). 
According to the recommended PSP technique, all scaffolds should be post-dilated 
with NC balloon. However, ACS patients have a potentially increased risk of over-expansion, 
disruption, and the effect of post-dilatation following its implantation [9, 10]. The ASSURE 
Registry (21.3% unstable angina) showed that a slight systematic oversizing of BVS, 
followed by high pressure post-dilatation, is safe and effective [28]. In turn, short-term results 
of the RAI registry (1,505 patients, 59% ACS) confirmed that high post-dilation rate (96.8%) 
might mitigate BVS-related events [29]. In a pooled analysis of the BVS Expand and BVS 
STEMI registries (351 patients, 72.6% ACS), post-dilation in ACS group was only 41.3% 
[30]. 
A comparison of BVS vs. everolimus eluting stent (EES) in STEMI patients with a 
high rate of post-dilation showed favorable mid-term results [31]. In the BVS STEMI first 
propensity score matching comparisons between 151 BVS patients and 151 EES patients, the 
MACE rate was higher in the BVS group (9.8% vs. 3.6%, p = 0.02, and TLR was 5.7% vs. 
1.3%, p = 0.05) [32]. Interestingly, the 30-day MACE rate in BVS patients without post-
dilatation was 6.8% and 3.6% in patients with post-dilatation. Of note, all BVS cases with 
acute scaffold thrombosis had no post-dilatation at the index procedure suggesting that 
optimization of the implantation technique is of paramount importance even in the acute 
setting. Imori et al. [33] also confirmed the importance of BVS post-dilation in the ACS 
setting. At 24 month follow-up, a higher rate of MACE was observed in BVS compared to 
EES in consecutive ACS patients before and after propensity score matching. However, after 
sensitivity analysis, MACE rates in BRS patients with post-dilation were significantly lower 
than in those without post-dilation and were comparable to EES patients (6.0% vs. 12.6% vs. 
4.7%, p < 0.001). scaffold thrombosis rates were only slightly lower in the BVS group with 
post-dilatation, but were higher in both BVS groups than in EES patients (2.0% vs. 2.6% vs. 
1.2%, p = 0.09). 
Contrarily to the ABSORB III 2-year results, the investigators did not find any relation 
between clinical outcomes with either the implantation technique (74% BVS post-dilation 
rate) or the diameter of the treated vessels or the presenting symptoms. However, among the 
patients in the scaffold group who had definite or probable device thrombosis, 19% had a 
residual diameter stenosis of 30% or greater; among the patients who did not have device 
thrombosis, 9% had a residual percent diameter stenosis of 30% or greater (p = 0.05) 
highlighting the importance to obtain maximal BVS expansion at the end of the procedure. In 
the present study, post-dilatation was applied in all patients in the PSP group without 
complications and only in 2 (1.5%) patients in the non-PSP group. 
 
Conclusions 
The implantation of BVSs according to the PSP-technique reduced rates of TVR, 
TVF, as well as MACE, compared with non-PSP-technique implantation during long-term 
observation. The PSP-technique for BVS implantation improves long-term results and should 
also be recommended for newer generations of bioresorbable scaffold. 
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Table 1. Baseline clinical characteristics. 
Characteristics PSP-technique Non-PSP-technique 
N 52 130 
Male  34 (65.4%) 94 (72.3%) 
Age [years] 60 ± 11 58 ± 11 
STEMI 7 (13.5%) 22 (16.9%) 
NSTEMI 11 (21.2%) 37 (28.5%) 
Unstable angina 24 (46.2%) 24 (53.8%) 
Cardiovascular risk factors:   
     Hypertension 34 (65.4%) 114 (87.7%) 
     Diabetes mellitus 9 (17.3%) 32 (24.6%) 
     IDDM 4 (7.7%) 12 (9.2%) 
Cardiovascular history:   
     Prior MI 14 (26.9%) 24 (18.5%) * 
     Prior CABG 2 (3.8%) 7 (5.4%) 
     Prior PCI 13 (25.0%) 35 (26.9%) 
Chronic kidney disease 4 (7.7%) 12 (9.2%) 
*p < 0.05, Mann-Whitney test or t-student test, as appropriate; CABG — coronary artery 
bypass grafting; MI — myocardial infarction; NSTEMI — non-ST-segment elevation 
myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-segment 
elevation myocardial infarction 
 
 
Table 2. Baseline angiography characteristics. 
*p < 0.05, Mann-Whitney test or t-student test, as appropriate; LAD — left artery descending; LCx — left 
circumflex artery; LM — left main; MACE — major adverse cardiovascular events; MLD — minimal lumen 
diameter; RCA — right coronary artery; RVD — reference vessel diameter 
 
Characteristics PSP-technique Non-PSP-technique 
Multivessel disease 16 (30.8%) 71 (55.0%) 
Target vessel location:   
LM 4 (7.7%) 0 (0.0%) * 
LAD 26 (50.0%) 62 (47.7%) 
RCA 10 (19.2%) 30 (23.1%) 
LCX 8 (15.4%) 22 (16.9%) 
Other 4 (7.7%) 16 (12.3%) 
Lesion type B2/C 32 (61.5%) 128 (98.5%) * 
Calcification 5 (9.6%) 1 (0.8%) * 
Bifurcation lesion 14 (26.9%) 14 (10.8%) * 
Thrombus 3 (5.8%) 5 (3.8%) 
RVD [mm] 3.1 ± 0.4 2.91 ± 0.4 
MLD [mm] 0.4 ± 0.2 0.31 ± 0.2 
Diameter stenosis [%] 87.3 ± 8.2 88.01 ± 6.7 
Qquantitative coronary analysis 34 (65.4%) 9 (6.8%) 
Visual estimate 18 (34.6%) 121 (93.2%) 
Total number of scaffolds 61 149 
Mean scaffolds per lesion 1.17 1.15 
Mean scaffold length per lesion  27.2 ± 10.7 22.5 ± 11.1 
Mean scaffold diameter per lesion  3.0 ± 0.4 3.0 ± 0.4 
Radial approach 50 (96.1%) 125 (96.1%) 
Pre-dilatation 52 (100%) 120 (92.3%) 
Mean pre-dilatation balloon diameter 
[mm] 
2.9 ± 0.5 2.7 ± 0.5 
Maximum pre-dilatation pressure [atm] 13.1 ± 2.3 13.5 ± 1.2 
Post-dilatation 52 (100%) 2 (0.5%) * 
Mean post-dilatation balloon diameter 
[mm] 
3.1 ± 0.8 3.5 ± 0.0 
Max post-dilatation pressure [atm] 17.8 ± 2.4 16.0 ± ???? 
Complications occurring any time during the procedure: 
MACE 0 (0.0%) 0 (0.0%) 
Dissection 2 (1.5%) 1 (1.9%) 
Distal embolism 0 (0.0%) 0 (0.0%) 
No-reflow 0 (0.0%) 0 (0.0%) 
Angiographic success 52 (100%) 130 (100%) 
Procedure success 52 (100%) 130 (100%) 
Table 3. Exclusion criteria.  
Known intolerance to aspirin, heparin, PLLA, everolimus, contrast material 
Active bleeding or coagulopathy or patients on chronic anticoagulation therapy 
Poor compliance 
Severe tortuous, calcified or angulated coronary anatomy of the study vessel 
Fibrinolysis prior to percutaneous coronary intervention 
 
 
Table 4. Results. 
Characteristics PSP-technique Non-PSP-technique 
All cause death 3 (5.8%) 4 (3.1%) 
Cardiac death 2 (3.8%) 2 (1.5%) 
Any MI 1 (1.9%) 10 (7.7%) 
Target vessel MI 1 (1.9%) 6 (4.6%) 
Scaffold thrombosis 0 (0%) 1 (0.8%) 
Target lesion revascularization 0 (0%) 7 (5.4%) 
Target vessel revascularization 1 (1.9%) 19 (14.6%)* 
TVF 3 (5.8%) 23 (17.7%)* 
MACE  4 (3.7%) 29 (22.3%)* 
*p < 0.05, Mann-Whitney test, as appropriate; MACE — major adverse cardiac events; MI — 
myocardial infarction; TVF — target vessel failure 
 
 
